Peptides
Mechanisms, research, benefits, limitations, and emerging applications.
98 articles in Peptides · page 6 of 9
The Placebo Problem in Peptide Research
Placebos produce measurable effects even when patients know they're inert — which is why peptide anecdotes can't be trusted.
Read →Collagen Peptides: One of the Few With Decent Human Data
An outlier in the peptide world — modest skin and joint evidence, with funding and quality caveats.
Read →Peptide Stacking: Why Combining Compounds Multiplies Unknowns
Even approved peptides carry combination warnings. Stacking gray-market compounds adds untested interaction risk on top of thin single-compound data.
Read →BPC-157 and Gut Health: A Closer Look at the Claims
BPC-157's gut data is its strongest — but it is almost entirely rodent work, with no controlled human trials.
Read →Hexarelin: The Forgotten Growth-Hormone Peptide
A potent GH secretagogue sidelined by tachyphylaxis and its cortisol and prolactin release — and what it taught the field.
Read →GHRP-6 vs GHRP-2: Comparing the Older Secretagogues
The first-generation GH peptides, their shared hormonal quirks, and why newer options often replaced them.
Read →BPC-157 for Tendons: What the Animal Studies Found
Reproduced rodent tendon results, essentially no controlled human trials. The honest state of the evidence.
Read →Reconstitution and Storage: The Science of Peptide Stability
Why handling matters, what degrades a peptide, and how that quietly changes whatever you're measuring.
Read →Receptor Agonists vs Antagonists: A Plain-Language Primer
The vocabulary you need to actually understand how a peptide is supposed to act.
Read →Peptide Side Effects: What the Safety Data Actually Shows
GLP-1 drugs have GI side effects in ~73% of users and a boxed thyroid warning. Gray-market peptides have almost no safety data at all.
Read →Why Most Peptide Claims Outrun the Evidence
The structural reasons the marketing is always years ahead of the science.
Read →Are Peptides Legal? The Regulatory Landscape in 2026
Approved drugs, a narrowing compounding lane, and a gray market built on a labeling loophole, explained.
Read →